INOVIQ Limited (IIQ)

Overview

INOVIQ Ltd is a biotechnology firm focused on the innovation of diagnostic and exosome-based solutions aimed at improving the diagnosis and treatment of cancer and various diseases. Operating in Australia and the United States, the company capitalizes on its research and development capabilities to offer advanced diagnostic tests. Initially established in 1983, the entity underwent a name change from BARD1 Life Sciences Limited to INOVIQ Ltd in December 2021, signifying a new chapter in its mission to revolutionize cancer diagnostics. Its headquarters are located in Notting Hill, Australia, serving as the central hub for its pioneering activities in the healthcare sector.

Products and Services

• hTERT Test:

An immunocytochemistry test developed as a supplementary tool alongside urine cytology testing to aid in the diagnosis of bladder cancer. This innovative approach enhances the accuracy and reliability of bladder cancer diagnostics, offering hope for more effective treatment strategies.

• EXO-NET:

A cutting-edge technology designed for the capture and isolation of exosomes from liquid biopsy samples. EXO-NET facilitates the analysis of exosomal content, paving the way for the development of non-invasive diagnostic tests for cancer and other diseases. This technology underscores INOVIQ’s commitment to advancing the field of liquid biopsy, offering potential for earlier detection and personalized medicine.

• Cancer Diagnostic Pipeline:

INOVIQ boasts an ambitious pipeline of blood tests currently under development for various cancers, including ovarian and breast cancer. These tests represent the forefront of the company’s efforts to expand its portfolio of cancer diagnostics, aiming to offer less invasive, more accurate, and early detection options for these life-threatening diseases.